Document: Presentations/kjnw0257.zip/kjnw0257.pdf
Category: Presentations
Processed: 2025-06-12T12:08:47.263112
Method: pymupdf+enhanced_ocr
Text Length: 21916 chars
==================================================

=== Page 1 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257

=== Page 1 Image 1 (OCR) ===
Te

McKinsey Vi First cut doc
& Company BEEEEEEEEE Numbers to be further refined

Yj
yy

Corporate
performance
diagnostics

Discussion document
Feb 2020

@endo

OME DET AL ALD PROPER E TARY ot of
fon ase Phas sole: a wilt abape: Pooper ssc PRG Kosi, 8 on ran es
Sb tyra x /

MCK-MAAG-2630461

=== Page 2 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257

=== Page 2 Image 1 (OCR) ===
Key issues

.

Opioid: Company is facing litigation related to opioid overuse across many states in US Settled liabilities with

Peete lara at ese er ererele crease stata a ee late et ase eal ela eal ele a eteialasreia.e.ctetai sleet eatsrereseraia a dnteaerelatarstetase.e1atarereresaserd

Oklahoma and case coming up with NY state Analyst estimate total potential liability range from USD 0 5B - 4 0B

Legal

Redacted

jee ses ese e tse inte area eaten eset a terest aera late rera Stele a erere a area. eieteatelei alerts arerelatesara areata aie lareiatea.eserearessteeseraterare

ia enn

Redacted

oie a laa isisiareisialaim sistas itision isielaisisiaiainieieiaa fs iaiatafisiaiose sistas sialon isieiaefeielao ne isie lara sciaiateisisioe isto in icisio ps ieiela ne feiain nis ieinieisisin a icie!

Sov

vn tou

McKinsey & Company

2

MCK-MAAG-2630461.000001

=== Page 3 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257

=== Page 3 Image 1 (OCR) ===
Summary

° .

fetetatmeeswararese'

Endo is well performing operationally with higher margins than peers. However, due to issues related to opioid crisis,

pete sR Bind id

Redacted

(atmnwrere sae: S ia iera ale ie asereyermsoreses

j growth is negative, cash flow did not cover liabilities, debt is below investment grade and

setae tere areata case te ieretetoeseatdiatolat eine taretata athlete atelaeiea aetna ae atarare lai eiete iar esn aera inten ejecta arelntale.eiat arate inieiarn interne ereiareiatelaseseterare:

company is facing large potential litigation liabilities

Redacted

lee rose eas a ier ees solar mees afore ye aterm ys ola ms aie rees a iereis siete ys oe ees alata ata mys ola ms ate mis oie eas siete ys oie e es calorie aia ie ela ae aie eee oie ais slat ess sie es e

McKinsey & Company

3

6 September 2020

MCK-MAAG-2630461 .000002

=== Page 4 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257

=== Page 4 Image 1 (OCR) ===
Summary

¢ Endo is well performing operationally with higher margins than peers. However, due to issues related to

Sia. Lisielelaiuiesaye tone a ieiaeieleisialeteioey

Redacted

opioid crisis, !

mca rn sapere msare asain; aiatea.srase.e+arererere

igrowth is negative, cash flow did not cover liabilities, debt is

below investment grade and company is facing large potential litigation liabilities

plate esata ta eraiaie arate is afaieia faimie aia ia ie era aie eraia ta aiaiasaafaie ies. efaieia ofa iaia- aia ia ie ara ate eraiasa aa.aseafaieis era ieia ofa ieia ernie ie ara ate arnia ss aacase aie

Redacted

ieee terete ere terete reenter

arene eter eee erate eee ere ete ee ee a eR ee A ne nn ne A ne RR en RR Re RR ne Rn ne A nn eR ne ne nnn nie ene en ein mia einen ieeiaieimimieiermimrerereie:

McKinsey & Company

a

6 September 2020

MCK-MAAG-2630461 .000003

=== Page 5 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257

=== Page 5 Image 1 (OCR) ===
Endo’s share price has declined ~90% in last 5 years mainly driven by

legal challenges and underperformance

Endo share price’

USD per share

= seamen arm emie

_ [revere rere rarer ererererer -

120

Mar ‘16: Sued by FTC along

wth others ‘or illegally blocking

lower-cos: generic versions of

Redacted

Redacted

Redacted

the Rrandeg. drugs Opana ER

!

|

|

ang Redacted!

eietee

piano mete etn em iatetm rina termed

:

eine tetera aterm erred

———————=

ae

Navsmigmemtnarenige ces

A Te Re

80

poate ere rerererererererererereress

mine te terete ey

Jun ‘17: Sued by Ohio Asorney General

alongwith ‘our other pharma companies ‘or

Redacted

‘heir alleged par: in dnung an opioid and

Prescnpion painkiller overdose epidemic

:

Lowi ini anim etapa re isielm ness iete re sas, -

i

i

:

Redacted |

Redacted

2

Yi

Nectmsevercieiases -

!

mieimiain rm imintnraimininrnteinvnd

|

through aggressive marke'ing ‘ac‘ics

ee ee ee

40 -

Jun 17: FDA reques's.

pain medication, Opana

Endo ‘o rerrove rs opioid

Redacted

ER, ‘ror the marke:

|

Ste taversieteversietevetsiets

:

Jan 15

Jul 15

Jan 16

Jul 16

Jan 17

Jul 17

Jan 18

Jul 18

Jan 19

Jul 19

Jan 20

t

7A bet

77

s:

y

SAP Capla Tet rays s

McKinsey & Company

i]

MCK-MAAG-2630461 .000004

=== Page 6 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257

=== Page 6 Image 1 (OCR) ===
Be ee ee ee

Redacted

nen Ene rn SEnE ESSENSE SEnE SSDS RENE SESE SEnE SESS SEnSSNE SESE SERS SESE SERSSnSSESnSEESSNSSESERSRESHSNSSRESHSSESIRSSNSSHSESSRESSESSSRESSSHSERSSRESSSESERSNSSHSRSSnSSOSSHSERSSSESOSSESSSESSSSSERSSNSSHSSESSRSSSSNSSRESNSSHSSESSRE SSSI SERSSESSHSnSSRSSHSSISSRSSNSSHSSSSSRESHSSNSTnSSNSSOSSRSSnSSESSNSTSSSNESESESERESSSSSTESSSESHSnSSEE SSSI SSSESNSSOSRSSRSSHSSNSESSNE SE SESSSE DESDE SRSONSSISS

AAG-2630461.000005

=== Page 7 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257

=== Page 7 Image 1 (OCR) ===
Be ee ee ee

Redacted

Tenner SEnE ESSENSE SERS SNS SE REEDED SERS SSE SERENE SESE SERS SESS SERSSnSSESESEES DSSS SERSNESHSNSSRESHSSESERSSNSSESnSSEESNSSSSSRESSSSHSSESSRESSSESERSNSSHSESSnS SSDS SERSSSESOSSnSSSESSSSESEnSSSSHSSESSnSSSSSSSnESNSSISSESSEESSSESERSSESSHSESSEE SSDS SSSSNSSHSSASSRESH SSN SInSSNS SOS SRSSRESESSNSTSSNESESESSRESSSNSTESSSESHSnSSnSSNSEESSSESNSSNSERSSRSSHSSNSISESNE SE SRSSEESSSSESEESONSSISS

AAG-2630461.000006

=== Page 8 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257

=== Page 8 Image 1 (OCR) ===
Be ee ee ee

Redacted

Tenner SEnE ESSERE SSE SEnE SSDS RENE SESE SEnE SESE SERSENE SESE SERS SESS SERSSnSSESnSEES SSDS SSRSNESHSEESSRESHSSESERSSNSSHSnSSRESSEESSRESSSHSSESSRESSSESERSESSHSRSSESSSSESERSSSESHSSESSSESSSSSERSSSSHSSESSRESOSSESSRESNSSHSSESSnESSSESEnSSNSSHSnSSRS SSDS SSnSNESHSSRSSSESHSSNSEnSSNSSHSSRSSRSSESSNSTSSSNESESESERESSSSSTnSSSESHSnSSESSNSEESSSISNSSSSERSSRSSHSSNSISSNE SE SEESSESSOSSESERSNSSISS

AAG-2630461.000007

=== Page 9 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257

=== Page 9 Image 1 (OCR) ===
Endo's revenue profile has remained flat and declined since 2016 driven

by both Branded and Gx segments

Endo's Revenue evolution by segment, 2014-19, USD bn, as reported

mista tet te crete terete terete reas

ieee tere eter terete re erate terete reer

Redacted

W@ US Branded - Specialty & Established Pharmaceuticals! _

5 GJS Genenc Pharmaceuticals

i wiererctaieseciniararsteiereciwiataciaiaves

Growth (2014-19),

Key takeaway

CAGR SE

Paet_Coubeshi uh tthines_ Sarna

f

40

8% p.a.

10% p.a.

| Redacted

eine teint eter terete reer

33

2

35

Branded Pharma portfolio

declining, driven by loss of

29

29

29

NA

marketing exclusivity for

|

certain drugs and voluntary

withdrawal of OPANA® ER

a

from the market since

FY2017

tard reiatescéeineridaieversins ‘

09

at

Redacted

03

05

03

a

20°4

20°9

aime terete eter terete reread

ee

Redacted

McKinsey & Company

)

[ee ee ee Ee Ee <

MCK-MAAG-2630461 .000008

=== Page 10 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257

=== Page 10 Image 1 (OCR) ===
Be ee ee ee

Redacted

Tne rn SEnE ESSER ENED S SERS ESSE SEnEnE SOS nSEnE SOS SE SERENE SESE SERS SESS SEnSSNS SES EASERS DSSS SSRSNESOSEESSRESHSSESERSSNSSESnSSSESSSESSRSSSSHSEESSRESSSESERSNSSHSnSSRSSESSESERSSNESOSSESSSESHSSNSEnSSSSHSSESSRSSSSSISSnESNSSUSSESSRESSSESERSESSHSnSSEESOSSESSSSNSSHSEASERESHSSISTnSSNSSUSSRSSRSSESSNSTSSSNESESESERESSSSSTESSSE SHS ASSESSHSSISSSISNSSOSERSSRSSHSSNSESESNE SE SESSESSSSSESEESNSSIS

AAG-2630461.000009

=== Page 11 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257

=== Page 11 Image 1 (OCR) ===
Be ee ee ee

Redacted

Cnn nen ne Sn SEnE ESSERE SSE SEnE ESSE SEnSnE SESE SEnE SESS SERSSNE SESE SERS SES SESERSSNSSESEASEES SSDS SSRSNESUSESSRESESSESERSSNSSHSESSRESSSSSSRSSNSSHSSESSRESSSESSRSNSSHSESSESSNSSSSERSSSESESSESSSESSSSSERSSSSHSSESSnSSSSESSnESNSSISEASSnE SSSI SERSSESSHSESSESSSSSSSRSSNSSHSSASERE SSSA SInSSNSSOSSnSSRSSESSNSTSSNESSSESERESSSSSSESSSESHSnSSEESHSENSSSESNSSSSRSSRSSHSSNSESSNE SE SRSSRSSSSSESEESONSSIS

=== Page 12 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257

=== Page 12 Image 1 (OCR) ===
Be ee ee ee

Redacted

nen Ene rn SEnE ESSERE SSE SEnE OSS SE RENE SOS SEnE SESSA SERENE SESE SSNS SESS SERSSnSSESnSEES SSDS SERESnESOSESSRESHSSESIRSSNSSESRSSRESNSSESSRESNSSHSEESSRESHSSESERSNSSHSnSSES SOSH SERSSSSSESnSSSESSSSSERSSSSHSSESSRSSSSSSSSESNSSISSESSEE SOSH SERSESSHSnSSRESOSSSSSSSNSSHSSnSSRESH SSE SInSSNSSOSSRSSRSSESSNSTSSNESESESERESSSSSTSSSSESHSnSSEESNSENSSSESNSSSSRSSRSSHSSNSISSNE SE SEESSRSDSSESERESNSSISS

=== Page 13 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257

=== Page 13 Image 1 (OCR) ===
Be ee ee ee

Redacted

Tne Ene nS nSEnE ESSERE SSE SERE SSDS RENE SESE SERS SES SESERSSnE SESE SERS SESS SERSSnSSESnSEES SSDS SERSNESOSNSSRESHSSESERSSNSSESRSSSESSSESSRESSSHSERSSRESHSSNSERSNSSHSnSSESSSSN SERENE SES SnSSSESSSSSERSSSSHSSESSRSSSSESSRESNSSISEESSNESSSSESERSESSHSnSSESSSSESSSSNSSHSSnSSEESHSSASEnSSNSSUSSRSSRSSESSNSTSSNESESESERESHSSSSTESSSESHSnSSEESHSSESSSISNSSSSEnSSRSSHSSNSESSNE SE SESSRSSSSSESEESNSSISS

=== Page 14 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257

=== Page 14 Image 1 (OCR) ===
Be ee ee ee

Redacted

nena nr nSEnE ESSENSE SEnE SSS SERENE SESE SEnE SESS SERSSnE SESE SERS SESS SERSSnSSESESEES DSSS SERESRESUSEESSRESESSESERSSNSSESnSSRESSSESSRESSSHSEESSRESSSESERESNSSHSSESSnSSSSNSEnSSSE SES SESSSESSSSSERSSSSHSSESSnSSSSSESSRSSNSSUSEESSRESSSESERSNSSHSRSSEESOSSESSnSSNSSHSEASSSESNSSNSInSSNSSUSSRSSRESESSNSTSSNESESESERESSSSSTESSSESHSnSSESSHSEESESESNSSOSRSSRSSHSSNSISSNE SE SRSSRSSSSSESEESONSSIS

=== Page 15 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257

=== Page 15 Image 1 (OCR) ===
Be ee ee ee

Redacted

Tne nner SEnE ESSER SEEDS SERS SOS SE RENE SSE SERE SES SE SERENE SESE SERS SOS SESERSSNS SES EESEES DSSS SSRSNESHSESSRESHSSESERSSNSSESnSSRESSSSSSRSSSSHSSRSSRE SOSH SERSNSSISESSESSSSESERSSSESOSSnSSSESSSSNSERSSSSHSSESSNSSSSESSnESNSSHSEASSRE SSSI SERSESSHSESSRSSHSSESSSSNESHSSASSRESSSESTnSSNSSUSSRSSRSSESSNSTSSSNESESESSRESHSSSSTSSSSESHSnSSESSNSSNSSSESNSSSSEnSSRSSHSSNSESSNE SE SRSSRSDESSESERSSSISS

=== Page 16 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257

=== Page 16 Image 1 (OCR) ===
ERR ES

Redacted

Tonner EnE DS nSEnE ES EnSE RSENS SSESEnESSSESERSSnE SO SnSSESSESSESESSSNSSESEESSRSSHSSISTnSSNSSESEISSEESISEISSRSNSSHSIESSEESHSSNSSRSSNSSHSSNSEEESHSENSSRSSNSSISSRSSRESHSSESERISNSSHSSRSSESSHSSNSERSNSSHSINSSSOSISSNSERSNSSHSnSSROSHSSNSIRSSNSSHSNSSEESHSSESERSSNSSHSnSSESSHSSESERSSNSSHSNSERESHSSNSENSNSSHSSRESEOSESEESTSSSNESHSESERESNSSNSTESSNESHSInSSESSHSENSSSESNSSOSEnSSEOSHSSISISSSNS SE SEESSES SSS DESEEEONSSO

=== Page 17 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257

=== Page 17 Image 1 (OCR) ===
ere tetere.

f]

Endo also has large potential litigation liabilities upto ~USD

peretese: <i

Redacted

Estimate

Liability

"If we consider Oklahoma to be a “typical” state (28th in population and 29th in GDP). Endo’s settlement

implies a nationwide liability around $500M.“ — Gabelli. Jan 14°, 2020

Opioid

"We estimate a fair value range of S2-4 based on our DCF (10% WACC. -1% terminal). using ~$3-4B

opioid charges paid over 10 years.” — Guggenheim, Nov 5", 2019

ieee tere eter eee re erate ete eee ete ee ee eR ee A ne RR ee A nn eR Rn RR RR RR nn A nn RR nein nn Rn ne a nn a ni ene ee einen einai nie eie erm eieieeiaiermi nite

Redacted

Linen eee ee ete ee ere ete a erate ete a ere ere ete ere ete ee a ee nn ee en nn ne nn nnn A ee A nn ne ee a eine nie nia eine nie nie einiaieieeia erm eieieeiarermrerererey -

sor

ssp

vila og Areal:

rl

vt

McKinsey & Company

7

MCK-MAAG-2630461 .000016

=== Page 18 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257

=== Page 18 Image 1 (OCR) ===
To be further refined

Summary

|

. _Endo i is well performin operationally with higher margins than peers. However, due to issues related to opioid crisis,

ted

Bis Siaveys Sintete tere ste ciate ys-siarme ys a)

“igrowth is negative, cash flow did not cover liabilities, debt is below investment grade and

“company is facing large potential litigation liabilities

en ee a a ne ne a ne a ee a a an ne ee ee ee See Se eee Se

Redacted

( ereiwie aia mia aia la ie are aera aia araiasa afaiaia.e alae aiaie ie ara ieia aia aia era ata afacase araiajo. eral ia ara leia aia aia a iata ie era a ta araiase araiasa.eraia isa faieie ara lerao

McKinsey & Company

18

6 September 2020

MCK-MAAG-2630461 .000017

=== Page 19 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257

=== Page 19 Image 1 (OCR) ===
Be ee ee ee

Redacted

Cnn nen ne Sn SEnE ESSERE SSE SEnE ESSE SEnSnE SESE SEnE SESS SERSSNE SESE SERS SES SESERSSNSSESEASEES SSDS SSRSNESUSESSRESESSESERSSNSSHSESSRESSSSSSRSSNSSHSSESSRESSSESSRSNSSHSESSESSNSSSSERSSSESESSESSSESSSSSERSSSSHSSESSnSSSSESSnESNSSISEASSnE SSSI SERSSESSHSESSESSSSSSSRSSNSSHSSASERE SSSA SInSSNSSOSSnSSRSSESSNSTSSNESSSESERESSSSSSESSSESHSnSSEESHSENSSSESNSSSSRSSRSSHSSNSESSNE SE SRSSRSSSSSESEESONSSIS

=== Page 20 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257

=== Page 20 Image 1 (OCR) ===
Future cash flows from operations would be used up to pay

litigation charges and interest expenses

Cumulative cash flow, FY2020-23, USD bn

Upside case

Downside case

iinet eter ete a erate er erate rer etere ete area re ere areata ererererereierererereie

CFO betore interest i

ieee tere eter te eter rete eater e teeta re ere eter eie aie eieieieie ere ererereierereiere:

Redacted

A

petite eerie ernie mieten niet miei mieten ieee

Assumptions:

& changes in WC

peel eee tere eset ere: APN en SP ne at te earl arr ean a en ee aT ST ST TST ere TT mse m,

Lragation charges

49

=

Redacted

bese sese sense tesesninseinvasninieiniesninsniniasnmeninvnsnins

!

Opioid litigation liability estimated to range from

USD 500M In Upside case to ~USD 4.0B in

Downside case (based on analyst reports).

ieee tere erent eter erent erate erate ererererereierereree:

assumed to be repaid by FY2023

"

"

"

"

"

"

"

"

"

Redacted

"

Redacted

"

"

"

"

"

pe :

Liner e re eee eee ete ete eee tee ere erecta re erate erate eee areata mere ieee ereieiereeieiererererereierereieia

i

Scarce SRP olay ba

McKinsey & Company

29

im eles n le tam mie tormialesoemia te tareta les ci eiate lara esormin let ara aie toma lesormietetaemie tas cinta tela mala iormia le aia ate iotai ale ormin ta aoa ates ornate tamale tormiale tai ate tataialatormintntomatesormia taser m ale tormtatasamiatetarmata

Redacted

ieee eter ete a erate re ete ere ere ere ee ern Rte ein ete eR eR RI ne Re RIA nn AIR nn A RR RIS eR RnR SIR nn A nn A Rn SIR nn An a a en ee nie aia nie a nin aia nina eiaaiaiaiaaeinieiaiaiemmimmimmimmmimmimrermiard

MCK-MAAG-2630461.000019

=== Page 21 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257

=== Page 21 Image 1 (OCR) ===
Be ee ee ee

Redacted

Tne rn SEnE ESSERE SSE SEnE SSDS nSnE SOS nSERE SOS SE SERENE SESE SSnSSES SE SERSSNSSESESEES SSDS SERESRESUSESSRESHSSESERSSNS SE SnSSEESSEESSRESSSHSSESSRESSSESSRSNSSHSEESSnSSHSSNSEnSSSESOSSESSSESSSESERSSSSHSSESSnSSSSESSRESNSSISEASSnE SSSI SERSSESSHSESSRESOSSESSnSNSSHSSASSEESHSSNSEnSSNSSOSSRSSRSSESSNSTSSNESESESERESSSSSTESSSESHSnSSEESHSEESSSISNSSOSEnSSRSSHSSNSISSNE SE SESSEE DESDE SERSSSIS

AAG-2630461.000020

=== Page 22 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257

=== Page 22 Image 1 (OCR) ===
Be ee ee ee

Redacted

Tne rn SEn ESSERE SSE SEnE SSDS nSEnE SESE SERE SESE SERENE SESE SERS SESE SEESSnSSESESEES DSSS SERSRESHSEESSRESHSSESERSSNSSESnSSEESNSESSSSESSSHSEESSRE SOSH SERSNSSHSSRSSESSSSNSERSSSS SES SSSSSESSSSSEnSSSSHSSESSnSSSSSESSSESNSSISEESSnE SSSI SEnSSNSSHSESSRSSSSSSSSSNSSHSSnSSEESHSSNSEnSSNSSOSSRSSRSSESSNSTSSNESESESERESSSSSTESSSESH STRESSES SHOES SSSISNSSSSERSSRSSHSSESISESNE SE SnSSEE SS SSESEREOSSOS

=== Page 23 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257

=== Page 23 Image 1 (OCR) ===
Be ee ee ee

Redacted

Tne nner SEnE ESSE n ERE SS SERS SOS SE RENE SOS nSEnE SESS SERSSNE SESE SERS SESS SERSSnSSESEESEEE SOSH SSRSNESISEESSRESHSSESIRSSNSSESnSSEESNSSESSRESSSHSERSSRESSSESSRISNSSHSRSSRSSSSESSnSSSSSESSESSSESSSSSERSSNSSHSSESSnSSS SE SSRESNSSISSESSRESSSESERSSESSHSESSRSSSSESSSSNSSHSSnSSRESHSSNSInSSNSSOSSRSSRSSESSNSTSSNESESESERE SSDS STESSSESHSnSSES SSSI SSSISNSSOSRSSRSSHSSNSISSNE SE SnSSES DESDE SEESOSSIS

AAG-2630461.000022

=== Page 24 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257

=== Page 24 Image 1 (OCR) ===
Be ee ee ee

Redacted

nen EnE rn SEnE ESSENSE SEnE SSSR EnE SESE SERS SES SE SERENE SE SEESSnS SESS SERSSNS SES EESEES DSSS SERSRESHSEESSRESHSSISERSSNSSESnSSRESNSSSSSRESSSHSEESSRESHSSESERSNSSHSRSSRSSHSSESERSSSESESSESSSESSSNSEnSSSSHSSESSRSSSSSSSnESNSSISEASSRESSSESERSESSHSRSSEESOSSESSSSNESHSEISSRESHSSNSInSSNSSUSSRSSRSSESSESTSSSNESESESERESHSSSSTESSSESHSnSSES SSSI SSSISNSSSSRSSRSSHSSNSISSNE SE SESSSESSSSESEEEONSSOS

AAG-2630461.000023

=== Page 25 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257

=== Page 25 Image 1 (OCR) ===
Analysts are concerned about Endo's ongoing opioid litigations,

ie ee ee eee eee te ere ee ee ee ere eee eee ere ere ere Mb areata eee einer eee ene ere meres,

Redacted

Vici aja naa ye efaiaia, efaiaie aisle ia ara aie. nraiote- are c so roa ierese ele nyaiaie apaiaia nia ata. araiaja-niaajs.naiayeerai—

iota mtaiaies area yeefaiaiearaiaie- ara la ia ara aie-asaiota-araiase aaa ia.eraias 1

‘

@. We are becoming more positive on ENDP from an opioid standpoint,! i

sate iarererererarare ata erate al araiarerelalarereaiaratarn mraiaeasarearmtarmiearmtnrarainy ‘

i

i

i

i

i

i

i

Redacted

Redacted

i

bien eet eee eee ere tee ere ieee eit ee ieieeie eieieieieeiiereieimieieies Roo voces cere recente rere rete ere rere sere ere re sete rere rete se rere re sesererereseseses

Gabelli, 14 Jan 2020

Soo epee a are ate eae a sre ese ate eretn esas a aa iera ea a = areata eae a are ase a ta asin esas eee ieee pe et = area

Sie eielave a ieiste eveiste eveieve etoile

atewtesei

Redac

rover

Redacted

|

inl e IS ae isla le SiS elas lala Sit iala Sisisle Sitisle ei ale islet eis alae isiale Sisial a eisisie eitisie we ela eS

‘However, ENDP’s!

ae

aed

and ongoing opioid litigation/headline risk add unique risks that are challenging to handicap and have weighed on the stock

RBC capital markets, 5" Nov 2019

§Petele cial Sle sie cin a ialaletsiatele otal GS a1inta Slat Sle cialele ciaiaie sialcle sisicie ataletese,

dact

miei

However, we continue to expect this dynamic to be

ovarananowea by’ the « ongoing opioid saga, , which in our view remains a very significant risk given the company's branded

Sie a She te avetete: ciie late iSiale ate eetatNEINE Swe wtaiSin wieiete sia winiaiS ae haiela aii alelewimiaiDeietete icin!

ee

apes Portfolio/mkt s share

ri

cted

felt ie ete er et er ete ee re ee eee Ieee eee mee memes mime

Redacted

JP Morgan, 5‘ Nov 2019

Sow

vail

1

McKinsey & Company

25.

MCK-MAAG-2630461 .000024

=== Page 26 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257

=== Page 26 Image 1 (OCR) ===
Be ee ee ee

Redacted

nena rn SEn ESSERE SSE SEnE SSDS RENE SESE SEnE SES SE SERENE SESE SERS SESS SEnSSNSSESESEES SSDS SERESRESHSASSRESESSESERSSNSSESnSSRESSSSSSRESSSHSEESSRESHSSESERSNSSHSSESSnSSSSESEnSSSS SOS SESSSESSSSSERSSNSSHSSESSnSSSSSSSSSESNSSISSASSEESSSESERSESSHSESSESSSSESSRSNESHSEASSRESHSSNSInSSNSSOSSRSSRSSESSNSTSSSnESUSESSRE SSDS STESSSESHSnSSESSNSEESSSESNSSOSEnSSRSSHSSNSESSNE SE SnSSEE DESDE SEESSSOSS

AAG-2630461.000025

=== Page 27 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257

=== Page 27 Image 1 (OCR) ===
Summary

¢ Endo is well performing operationally with higher margins than peers. However, due to issues related to opioid crisis,

i

cictaiate ate alata larala rere atte elec

Redacted

bps ah ee

igrowth is negative, cash flow did not cover liabilities, debt is below investment grade and

company is facing large potential litigation liabilities

petite tte ier er ee er ee eee ems mm e memes mrmrmem mimes

Redacted

Seles esei aerate aera late are latecm ear erntaeiela este etetstalee ist aerea eaten ese aera ine ate a erate melee ereialararelateieteiaretna cle iarerateleseieieiereisteaseraterare!

McKinsey & Company

27

6 September 2020

MCK-MAAG-2630461 .000026

=== Page 28 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257

=== Page 28 Image 1 (OCR) ===
ERR ES

Redacted

Tonner EnE DS nSEnE ES EnSEnSEnE SE SESEnESSSESERSEnESESnSSESSHSSESESSSNSSESESSRSSHSSISEnSSNSSUSEESSESSISSISSRESNSSHSInSSEESHSSNSIRSNSSHSSNSSEESHSENSSRISNSSHSSRSSRESHSSNSERISNSSHSTNSSESSHSSNSEnSNSSHSSNSSSOSHS=NSENSESSHSNSSNSSHSSNSIRESNSSHSENSSEESHSSESERSSNSSHSNSEESSHSSISSRSSNSSHSINSERESHSSNSInSNSSNSRESEOSHSSNSTSSSNESHSESERESNSSNSTESSNESHSInSSEOSNSENSSSESNSSOSERSSEESHSSESESSSNS DE SERSSES SES SESEEEONSSOSS

AAG-2630461.000027

=== Page 29 ===
Source:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257

=== Page 29 Image 1 (OCR) ===
Be ee ee ee

Redacted

Tne rn SEnE ESSERE SSE SEnE SSDS nSnE SOS nSERE SOS SE SERENE SESE SSnSSES SE SERSSNSSESESEES SSDS SERESRESUSESSRESHSSESERSSNS SE SnSSEESSEESSRESSSHSSESSRESSSESSRSNSSHSEESSnSSHSSNSEnSSSESOSSESSSESSSESERSSSSHSSESSnSSSSESSRESNSSISEASSnE SSSI SERSSESSHSESSRESOSSESSnSNSSHSSASSEESHSSNSEnSSNSSOSSRSSRSSESSNSTSSNESESESERESSSSSTESSSESHSnSSEESHSEESSSISNSSOSEnSSRSSHSSNSISSNE SE SESSEE DESDE SERSSSIS

AAG-2630461.000028